If not, please take a few moments to fill out the form below. It’s free, and ensures that you receive regular alerts to the latest clinical news and other content.

Keep me logged in Forgot your password?

Please wait...

Please wait...

High, Low PTH Raises Hypercalcemia Risk

May 13, 2012

NATIONAL HARBOR, Md.—Low and high levels of parathyroid hormone (PTH) are associated with hypercalcemia, according to a study of 106,760 hemodialysis patients presented at the National Kidney Foundation 2012 Spring Clinical Meetings suggest.
 

Novel Formulation Corrects Vitamin D, Lowers iPTH

May 13, 2012

NATIONAL HARBOR, Md.—An investigational treatment safely and effectively lowers elevated plasma intact parathyroid hormone (iPTH) levels in patients with stage 3 or 4 chronic kidney disease and vitamin D deficiency, researchers reported at the National Kidney Foundation 2012 Spring Clinical Meetings.
 

SHPT Linked to Vitamin D Deficiency in CKD Patients

May 12, 2012

NATIONAL HARBOR, Md.—Vitamin D deficiency is strongly associated with secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), according to data presented at the National Kidney Foundation (NKF) 2012 Spring Clinical Meetings.
 

Labs May Vary in iPTH Measurements

May 12, 2012

NATIONAL HARBOR, Md.—Laboratories can differ in their measurements of intact parathyroid hormone (iPTH) levels, resulting in varying treatment approaches for hemodialysis (HD) patients depending on the iPTH assay used, researchers reported at the National Kidney Foundation Spring Clinical Meetings.
 

CKD Patients May Need Higher 25D Levels

May 11, 2012

NATIONAL HARBOR, Md.—Levels of 25-hydroxyvitamin D (25D) higher than 20 ng/mL would be required to normalize intact parathyroid hormone (iPTH) in patients with stages 3 and 4 chronic kidney disease (CKD) with vitamin D insufficiency and secondary hyperparathyroidism, researchers concluded in a study presented at the National Kidney Foundation 2012 Spring Clinical Meetings.
 

Calcitriol as Effective as Vitamin D Analogues, but Cheaper

May 11, 2012

NATIONAL HARBOR, Md.—Oral calcitriol is as effective as vitamin D analogues for treating secondary hyperparathyroidism (SHPT) in hemodialysis patients but is more cost effective, according to a study presented at the National Kidney Foundation 2012 Spring Clinical Meetings.
 

Calcifediol May Improve PTH Control, Nutritional Status

November 12, 2011

PHILADELPHIA—Adequate doses of calcifediol can correct 25-hydroxyvitamin D deficiency and improve malnutrition-inflammation status in hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT), researchers reported at Kidney Week 2011.
 

Cinacalcet Plus Low-Dose Vitamin D Improves SHPT Treatment

November 12, 2011

PHILADELPHIA—Cinacalcet plus low-dose vitamin D provides a more effective approach to treating secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients, according to findings presented at Kidney Week 2011.
 

Uncontrolled SHPT On the Rise in Blacks Since Debut of 'Bundling'

November 12, 2011

PHILADELPHIA—Uncontrolled secondary hyperparathyroidism (SHPT) has been on the increase among black hemodialysis (HD) patients since the recent implementation of the federal government's prospective payment system for dialysis services, researchers reported at Kidney Week 2011.
 

Untreated SHPT Increases Mortality Risk

November 11, 2011

PHILADELPHIA—Untreated secondary hyperparathyroidism (SHPT) is associated with increased mortality risk in hemodialysis (HD) patients, according to a report presented at Kidney Week 2011.
 

Treating SHPT with Cinacalcet Lowers Phosphorus

November 11, 2011

PHILADELPHIA—Serum phosphorus levels in hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT) decrease during treatment with cinacalcet, data presented at Kidney Week 2011 show. This effect occurs regardless of baseline SHPT severity.
 

Two Vitamin D Analogues Show Similar Efficacy for SHPT

November 11, 2011

PHILADELPHIA—Alfacalcidol and paricalcitol have similar efficacy in suppressing secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients researchers reported at Kidney Week 2011.
 

Vitamin D Regimen May Treat SHPT in Renal Transplant Patients

November 10, 2011

PHILADELPHIA—Cholecalciferol with or without doxercalciferol may be an appropriate treatment for secondary hyperparathyroidism (SHPT) in kidney transplant recipients, according to the findings of a small study presented at Kidney Week 2011.
 

High PTH and FGF-23 Predict Vascular Calcification

November 10, 2011

PHILADELPHIA—Elevated levels of serum parathyroid hormone (PTH) and fibroblast growth factor-23 (FGF-23) are associated with an increased likelihood of progression of vascular calcification (VC) in hemodialysis patients, French researchers reported at Kidney Week 2011.
 

Study Identifies Predictors of Cinacalcet Use After Transplantation

November 10, 2011

PHILADELPHIA—The dose of cinacalcet dialysis patients receive prior to renal transplantation and their time on dialysis appear to be the most important factors associated with reintroduction of the drug during the first year following transplantation, Spanish researchers reported at Kidney Week 2011.
 

Paricalcitol Superior for Lowering iPTH

July 18, 2011

The drug was more likely than cinacalcet to achieve a 50 percent or greater decrease in iPTH from baseline.
 

Antioxidant Nutraceutical May Help Treat Secondary Hyperparathyroidism

April 30, 2011

LAS VEGAS—A novel multivitamin antioxidant nutraceutical may be useful in the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients, according to data reported at the National Kidney Foundation's Spring Clinical Meetings.
 

Inpatient Savings May Offset Cinacalcet Costs

April 29, 2011

LAS VEGAS—Inpatient cost savings may offset the costs of patient adherence to cinacalcet therapy, according to study findings presented at the National Kidney Foundation's Spring Clinical Meetings.
 

Paricalcitol Found Better for Lowering PTH

April 09, 2011

VANCOUVER, B.C.—Paricalcitol is more effective than ergocalciferol at lowering parathyroid hormone (PTH) levels in patients with chronic kidney disease (CKD) stages 3 and 4 and who have vitamin D deficiency and secondary hyperparathyroidism, data suggest.
 

Cinacalcet May Reduce ESA Use

February 23, 2011

PHOENIX—Cinacalcet hydrochloride (CH) treatment in dialysis patients with secondary hyperparathyroidism may improve responsiveness to an erythropoiesis-stimulating agent (ESA) by reducing systemic inflammation, resulting in decreased ESA requirements, new data suggest.
 

FGF-23 Linked to Cinacalcet Use

November 20, 2010

Fibroblast growth factor 23 (FGF-23) is positively associated with cinacalcet use, calcium, and phosphorus in hemodialysis (HD) patients, according to a study presented at Renal Week 2010 in Denver.
 

SHPT in Dialysis Patients Associated with Greater Mortality, Morbidity

November 20, 2010

New data presented at Renal Week 2010 in Denver confirm the high morbidity and mortality associated with secondary hyperparathyroidism (SHPT) in dialysis patients, emphasizing the need for early referral as well as other therapeutic interventions.
 

Oral Paricalcitol May Have Similar Efficacy to Oral Calcitriol

November 20, 2010

Oral paricalcitol (OP) appears to have similar efficacy and safety compared with oral calcitriol (OC) in dialysis patients with secondary hyperparathyroidism (SHPT), according to results from a randomized, controlled trial presented at Renal Week 2010 in Denver.
 

Cinacalcet for SHPT Safe, Effective in Renal Transplant Recipients

November 20, 2010

Cinacalcet is a safe and effective option for treating hypocalcemia and secondary hyperparathyroidism (SHPT) in renal transplant recipients, according to a new German study presented at Renal Week 2010 in Denver.
 

Elevated PTH May Increase Short-Term Mortality Risk in CKD Patients

November 19, 2010

Higher parathyroid hormone (PTH) levels are associated with an increased risk of death, possibly because of a higher prevalence of metabolic syndrome as well as other possible pathways according to a study presented at Renal Week 2010 in Denver.
 

Cinacalcet May Reduce Mortality in HD Patients with SHPT

November 19, 2010

Cinacalcet may help reduce mortality in hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT) in the "real world," Japanese researchers reported at Renal Week 2010 in Denver.
 

Cinacalcet Shows Promise for SHPT in Peritoneal Dialysis Patients

November 18, 2010

Cinacalcet appears to be safe and effective for long-term use in the treatment of secondary hyperparathyroidism (SHPT) in peritoneal dialysis (PD) patients, according to a new study presented at Renal Week 2010 in Denver.
 

Post-Transplant Cinacalcet May Be An Option

November 02, 2010

Cinacalcet may be useful for treating hyperparathyroidism after renal transplantation, new findings suggest.
 

Study Examines Impact of Ergocalciferol on Markers of Bone and Mineral Metabolism

June 18, 2010

Weekly (50,000 units) and monthly doses (50,000 units) of ergocalciferol treatment does not significantly impact markers of mineral metabolism (MM) in chronic hemodialysis (HD) patients, a study suggests.
 

Thrice-Weekly Post-Dialysis Cinacalcet A Viable Option

June 18, 2010

New approach may ease problems with noncompliance, according to researchers.
 

SHPT Treatment May Have CAC Benefit

June 10, 2010

Cinacalcet plus low-dose vitamin D for secondary hyperparathyroidism yielded encouraging results
 

Polycystic Kidney Disease Affects PTH-Related Mortality

April 17, 2010

Very high and very low parathyroid hormone (PTH) levels are associated with the highest mortality rates in hemodialysis (HD) patients.
 

Paricalcitol Improves Survival Regardless of Baseline iPTH Levels

April 17, 2010

Use of paricalcitol for hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT) is associated with a significant improvement in survival independent of baseline levels of intact parathyroid hormone (iPTH) compared with patients who have untreated SHPT.
 

Cinacalcet Plus Low-Dose Vitamin D May Slow CAC Progression

April 17, 2010

Cinacalcet plus low-dose vitamin D therapy may improve biochemical control of secondary hyperparathyroidism (SHPT) and attenuate progression of coronary artery calcification (CAC) compared with flexible vitamin D therapy alone in hemodialysis (HD) patients.
 

Paricalcitol-Treated Hemodialysis Patients May Require Less Erythropoietin

April 16, 2010

Long-term hemodialysis (HD) patients who receive paricalcitol as treatment for secondary hyperparathyroidism (SHPT) may require less erythropoietin than those who receive no SHPT treatment, according to new data presented at the National Kidney Foundation's 2010 Spring Clinical Meetings.
 

Post-Dialysis Dosing of Cinacalcet May Address Noncompliance

April 16, 2010

Although daily dosing of cinacalcet may be an optimal treatment for secondary hyperparathyroidism (SHPT) compared with other dosing regimens, thrice-weekly post-dialysis dosing may be a viable option when daily dosing is ineffective because of patient noncompliance or other factors.
 

Low Vitamin D After Renal Transplantation May Be Underrecognized

April 16, 2010

Low serum 25-hydroxyvitamin D (25 D) levels may be playing a role in bone disease among renal transplant recipients, researchers reported here at the National Kidney Foundation's Spring Clinical Meetings.
 

Monthly Monitoring of Parathyroid Hormone May Be Optimal

April 15, 2010

Monthly rather than quarterly monitoring of parathyroid hormone (PTH) may be better for chronic hemodialysis (HD) patients.
 

Cinacalcet Effective for Persistent Post-Transplant HPT

April 15, 2010

Cinacalcet appears to be a safe and effective agent in the long-term management of persistent post renal transplant hyperparathyroidism.
 

Parathyroid Gland Size May Affect Cinacalcet Response

January 15, 2010

Parathyroid gland enlargement may delay the response of secondary hyperparathyroidism to cinacalcet, Japanese researchers reported in Nephron Clinical Practice (2009; published online ahead of print).
 

Researchers Link Elevated PTH to High Uric Acid

November 01, 2009

Elevated serum parathyroid hormone levels are associated with higher serum uric acid levels in the U.S. adult population, investigators reported at ASN's Renal Week 2009.
 

Specialty Pharmacy Improves Control of Secondary Hyperparathyroidism

November 01, 2009

Participation in a specialty pharmacy improved control of secondary hyperparathyroidism in hemodialysis patients, researchers reported at ASN's Renal Week 2009.
 

Cinacalcet Safely Treats Persistent Post-Kidney-Transplant Hyperparathyroidism

November 01, 2009

Cinacalcet therapy is safe and effective for treating persistent hyperparathyroidism after renal transplantation, British researchers reported at ASN's Renal Week 2009. The medication is not associated with allograft dysfunction or significant adverse effects.
 

Elevated Parathyroid Hormone Linked to Obesity in CKD Patients

November 01, 2009

Obesity in CKD patients is associated with increased parathyroid hormone levels independent of estimated glomerular filtration rate, according to a study presented at ASN's Renal Week 2009.
 

Ergocalciferol and Cholecalciferol Can Both Correct 25-Hydroxyvitamin D Deficiency

October 31, 2009

Ergocalciferol 50,000 units per week and cholecalciferol 2,000 units per day can both correct 25-hydroxyvitamin D (25-OHD) deficiency within two months, but ergocalciferol recipients may achieve higher 25-OHD levels, according to researchers.
 

PTH Response to Calcitriol Reduced in African-American CKD Patients

October 31, 2009

Among patients with stages III-IV CKD, African-American race is associated with a decreased parathyroid hormone response to oral calcitriol, according to a study presented at ASN's Renal Week 2009.
 

Loop Diuretics Raise Risk of Secondary Hyperparathyroidism

October 31, 2009

Loop diuretics increase the risk of secondary hyperparathyroidism in CKD patients, but concurrent use of thiazide diuretics attenuate that risk, data suggest according to a study that was presented at ASN's Renal Week 2009.
 

Cinacalcet Effective for Refractory Hyperparathyroidism

October 31, 2009

Cinacalcet showed long-term efficacy in reducing serum parathyroid hormone and calcium levels in renal transplant patients with refractory tertiary hyperparathyroidism, according to a study presented at ASN's Renal Week 2009.
 

Vitamin D Insufficiency Common in Dialysis Patients with Secondary Hyperparathyroidism

October 30, 2009

Nutritional vitamin D deficiency is widespread among hemodialysis patients with secondary hyperparathyroidism, and few receive nutritional vitamin D supplementation, according to a study presented at Renal Week 2009.
 

High iPTH Levels Increase the Risk of Death, Need for Renal Replacement Therapy

October 30, 2009

Intact parathyroid hormone levels higher than 50 pg/mL in patients with stage 3 or 4 CKD are associated with an increased risk of death or the need for renal replacement therapy, data show according to a study presented at ASN's Renal Week 2009.
 

Alfacalcidol Vs. Calcidol for Secondary Hyperparathyroidism

October 29, 2009

Oral alfacalcidol is effective in controlling secondary hyperparathyroidism with an adjusted dose 1.5 times that of oral calcitriol, a study showed.
 

Cinacalcet May Aid in Bone Remodeling After Renal Transplantation

October 29, 2009

Cinacalcet treatment following renal transplantation is associated with improved bone remodeling, a study found.
 

Higher PTH Levels Associated with Heart Failure

October 29, 2009

Among older adults, higher parathyroid hormone (PTH) levels are associated with heart failure and lower serum levels of 25-hydroxyvitamin D (25-OHD) are associated with all-cause mortality and myocardial infarction (MI).
 

Left Ventricular Hypertrophy Not Independently Linked to Vitamin D Deficiency

October 29, 2009

The concentration of 25-hydroxyvitamin D (25-OHD) is not independently associated with left ventricular hypertrophy (LVH), researchers have concluded.
 

IV Calcitriol May Prevent Parathyroid Gland Growth

December 10, 2008

IV calcitriol treatment in patients with early-stage secondary hyperparathyroidism prevents parathyroid (PT) gland growth, researchers report.
 

Ethanol May Ease Secondary Hyperparathyroidism Post-Tx

November 01, 2007

Percutaneous ethanol injection therapy (PEIT) is a useful and safe treatment alternative for patients with persistent post-transplant secondary hyperparathyroidism, researchers in Argentina report.
 

Obesity, Hyperparathyroidism Linked in CKD

August 16, 2007

Elevated BMI is associated with secondary hyperparathyroidism in non-dialysis CKD patients, especially patients who have evidence of malnutrition and inflammation, a study found.
 

High PTH Common Post-Transplant

August 01, 2007

Hyperparathyroidism is common in long-term transplant recipients, findings suggest.
 

Paricalcitol Works Safely

July 01, 2007

Paricalcitol decreases intact parathyroid hormone (iPTH) levels in children receiving hemodialysis while not causing significant changes in serum calcium, phosphorus, or Ca x P product values, a study found.
 

BMD May Be Decreased Post-Transplant

January 01, 2007

Bone mineral density (BMD) may be reduced and parathyroid hormone (PTH) levels elevated in long-term renal transplant patients with good graft function, according to Swedish researchers.
 
Popular Topics
Acute Kidney Injury AKI Androgen Deprivation Anemia Benign Prostatic Hyperplasia Bladder Cancer BPH Cardiovascular Disease Chronic Kidney Disease Circumcision CKD CVD Diabetes Dialysis End-stage Renal Disease Hemodialysis Kidney Cancer Overactive Bladder Prostate Cancer PSA Renal Cell Carcinoma Secondary Hyperparathyroidism Transplantation Urinary Incontinence Urology

 

© 2012 Haymarket Media, Inc.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions